Evidence map›Paper›PMID 38094286›Full record

Trial reportIranian journal of medical sciences2023

The Added-on of

Hamid Zare, Seyed Hesamedin Nabavizdeh, Amir Mohamad Jaladat, Mohamad Mehdi Zarshenas, Mozhgan Moghtaderi, Atefeh Basirat, Nahid Nasri

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Iranian journal of medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hamid ZareDepartment of Persian Medicine; School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Seyed Hesamedin NabavizdehDepartment of Pediatrics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Amir Mohamad JaladatTraditional Medicine and History of Medicine Research Center, Department of Persian Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohamad Mehdi ZarshenasMedicinal Plants Processing Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mozhgan MoghtaderiAllergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Atefeh BasiratHealth System Research, Vice Chancellor of Treatment, Shiraz University of Medical Sciences, Shiraz, Iran.
Nahid NasriHealth System Research, Vice Chancellor of Treatment, Shiraz University of Medical Sciences, Shiraz, Iran.
Shiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although antihistamines are the first-line treatment for chronic spontaneous urticaria (CSU), 50% of patients don't respond to standard doses. In this study, the effectiveness of Methods: This double-blind randomized clinical trial was conducted in Shiraz between December 2019 and December 2020. 64 patients with CSU who had experienced hives for at least six weeks and did not respond to the usual treatments were enrolled in the study. They were randomly assigned to intervention and control groups using permuted block random allocation. For four weeks, the intervention group received 7.5 mL Results: Before the intervention, there was no statistically significant difference between the two groups' mean of UAS (P=0.490) and sleep quality (P=0.423). During the follow-up, UAS in the intervention group was significantly lower (P=0.001). Moreover, this difference was significant on the day 28 (P=0.046). During the follow-up, the quality of sleep in both groups improved significantly, and this improvement was more significant in the intervention group. Conclusion:

Indexed as

Chronic UrticariaUrticariaZiziphusChronic DiseaseHistamine H1 AntagonistsHumansPlant ExtractsHistamine H1 Antagonistsjujube extractPlant ExtractsChronic urticarialQuality of lifeSleep qualityZiziphus, jujube

Identifiers

PMID38094286
PMCPMC10715122
OpenAlexW4389800835

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.